Published in Postgrad Med J on January 01, 1995
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
Prevalence of hypercalcemia among cancer patients in the United States. Cancer Med (2016) 0.89
Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag (2015) 0.85
Multifactorial hypercalcemia and literature review on primary hyperparathyroidism associated with lymphoma. Case Rep Endocrinol (2014) 0.76
Hypercalcaemia in cancer. BMJ (2005) 0.75
Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med (1990) 2.76
Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med (1990) 2.43
Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet (1992) 2.17
Hypercalcaemia: changing causes over the past 10 years. BMJ (1992) 1.43
Development and validation of an immunoradiometric assay of parathyrin-related protein in unextracted plasma. Clin Chem (1991) 1.22
Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy. Bone Miner (1991) 1.02
Primary hyperparathyroidism. Clinical presentation and factors influencing clinical management. Endocrinol Metab Clin North Am (1989) 0.96
Parathyroid hormone-related protein as a tumour marker in humoral hypercalcaemia associated with occult malignancy. Postgrad Med J (1993) 0.95
Malignancy and concomitant primary hyperparathyroidism. J Surg Oncol (1988) 0.94
Parathyroid hormone-related protein: structure, function, and measurement. Clin Chem (1992) 0.90
Coincidental occurrence of primary hyperparathyroidism and cancer-associated hypercalcaemia in a middle-aged man. Clin Endocrinol (Oxf) (1993) 0.85
Clinical and laboratory studies of a new immunoradiometric assay of parathyroid hormone-related protein. Clin Chem (1993) 0.84
Treatment of hypercalcaemia of malignancy. Baillieres Clin Endocrinol Metab (1990) 0.81
Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet (1992) 2.17
1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res (2000) 2.01
Serum 1,25-dihydroxyvitamin D may be related inversely to disease activity in breast cancer patients with bone metastases. J Clin Endocrinol Metab (1997) 1.79
Thyroid function in adults with Down's syndrome. J Clin Endocrinol Metab (1977) 1.78
Tamm-Horsfall urinary glycoprotein. The chemical composition. Biochem J (1970) 1.77
COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer (2004) 1.59
Prospective randomized controlled trial of preservation of the intercostobrachial nerve during axillary node clearance for breast cancer. Br J Surg (1998) 1.59
Assessment of hormone dependence of comedo ductal carcinoma in situ of the breast. J Natl Cancer Inst (1997) 1.58
Cholecystectomy: a study of patient satisfaction. J R Coll Surg Edinb (1993) 1.55
Semi-automated radioimmunoassays for total serum thyroxine and triiodothyronine. Clin Chim Acta (1975) 1.53
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol (2011) 1.51
Can preoperative factors predict for residual malignancy after breast biopsy for invasive cancer? Ann R Coll Surg Engl (1995) 1.47
Abdominal symptoms, hypercalcaemia and apathetic hyperthyroidism: treatment with pamidronate. Br J Clin Pract (1994) 1.47
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer (2001) 1.46
Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res (1994) 1.43
Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcaemia in two hospital populations. Clin Endocrinol (Oxf) (1994) 1.42
Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab (1999) 1.42
Parathyroid hormone related protein and hypercalcaemia in breast cancer. BMJ (1991) 1.41
A critical evaluation of separation methods in radiommunoassay for total triiodothyronine and thyroxine in unextracted human serum. Ann Clin Biochem (1974) 1.34
Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer (1992) 1.31
Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev (2001) 1.27
Effect of fenclofenac on thyroid-function tests. Lancet (1980) 1.27
Laboratory assessment of prolactin status. Ann Clin Biochem (1979) 1.25
The acid and enzymic hydrolysis of O-acetylated sialic acid residues from rabbit Tamm-Horsfall glycoprotein. Biochem J (1972) 1.20
Tamm-Horsfall urinary glycoprotein. The subunit structure. Biochem J (1970) 1.20
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity. Br J Cancer (2006) 1.18
The chemical composition and electron microscopic appearance of a protein derived from urinary casts. Biochim Biophys Acta (1970) 1.16
Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer (2006) 1.13
Hidden dangers of sliced bread. Br Med J (Clin Res Ed) (1984) 1.12
Treatment of a malignant pancreatic endocrine tumour secreting parathyroid hormone related protein. BMJ (1990) 1.11
Prognostic significance of oestrogen and progestogen receptor activities in breast cancer. Br J Surg (1987) 1.07
The radioimmunoassay of thyroxine in unextracted human serum. Clin Endocrinol (Oxf) (1974) 1.05
Patterns of ACTH and cortisol pulsatility over twenty-four hours in normal males and females. Clin Endocrinol (Oxf) (1990) 1.04
A drip is unnecessary after cholecystectomy. J R Coll Surg Edinb (1992) 1.03
Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. BMJ (1996) 1.03
Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer (2007) 1.01
The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Br J Cancer (2003) 1.00
Evidence of significant apoptosis in poorly differentiated ductal carcinoma in situ of the breast. Br J Cancer (1998) 1.00
Rabbit Tamm-Horsfall urinary glycoprotein. Chemical composition and subunit structure. Biochem J (1971) 0.99
The radioimmunoassay of 3,3',5' - triiodothyronine (reverse T3) in unextracted human serum. Clin Endocrinol (Oxf) (1976) 0.99
Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst (2000) 0.98
The role of Robertson's cooked-meat broth in the bacteriological evaluation of surgical specimens. J Med Microbiol (1985) 0.97
Parathyroid hormone related protein in hypercalcaemia of Hodgkin's disease. J Clin Pathol (1992) 0.97
Carcinoma of the breast presenting as a thyroid mass. Eur J Surg (1997) 0.96
Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int J Oncol (2007) 0.95
Parathyroid hormone-related protein as a tumour marker in humoral hypercalcaemia associated with occult malignancy. Postgrad Med J (1993) 0.95
Effects of soy-protein supplementation on epithelial proliferation in the histologically normal human breast. Am J Clin Nutr (1998) 0.94
Are the lesions of duct ectasia sterile? Br J Surg (1985) 0.94
Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ. Cancer (2001) 0.94
Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. Br J Surg (2005) 0.93
Adrenocorticotrophin (ACTH) deficiency undetected by standard dynamic tests of the hypothalamic-pituitary-adrenal axis. Clin Endocrinol (Oxf) (1988) 0.92
Value of the Van Nuys Prognostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg (2003) 0.92
Direct 125I-radioligand assays for serum progesterone compared with assays involving extraction of serum. Clin Chem (1982) 0.92
Polyamines in breast cancer. Br J Surg (1984) 0.92
Thyroid function tests in patients with familial dysalbuminaemic hyperthyroxinaemia (FDH). Ann Clin Biochem (1986) 0.92
Intrauterine hypothyroidism due to antithyroid-drug therapy for thyrotoxicosis during pregnancy. Lancet (1978) 0.91
Investigation of mammary epithelial cell-bone marrow stroma interactions using primary human cell culture as a model of metastasis. Int J Cancer (1997) 0.91
Periductal inflammation and cigarette smoke. J Am Coll Surg (1994) 0.91
Gastric surgery and the risk of subsequent colorectal cancer. Br J Surg (1985) 0.90
Effects of a pure antiestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ. Cancer Res (2000) 0.90
Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev (2012) 0.89
The importance of complete excision in the prevention of local recurrence of ductal carcinoma in situ. Br J Cancer (1998) 0.89
Long term results of a randomised prospective study of preservation of the intercostobrachial nerve. Eur J Surg Oncol (2003) 0.89
Serum vascular endothelial growth factor in breast cancer. Anticancer Res (2007) 0.89
The effect of ketanserin, a specific serotonin antagonist on the PRL, GH, ACTH and cortisol responses to hypoglycaemia in normal subjects. Clin Endocrinol (Oxf) (1984) 0.89
Propranolol, triiodothyronine, reverse triiodothyronine and thyroid disease. Clin Endocrinol (Oxf) (1979) 0.88
Tumour cyclic AMP binding proteins and endocrine responsiveness in patients with inoperable breast cancer. Br J Cancer (1987) 0.88
Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation. Br J Surg (2001) 0.88
Assessment of apoptosis in human breast tissue using an antibody against the active form of caspase 3: relation to tumour histopathological characteristics. Br J Cancer (2001) 0.88
Mammillary fistula. Br J Surg (1987) 0.88
Lobular carcinoma of the breast can be managed by breast-conserving therapy. Br J Surg (1995) 0.87
Hyperprolactinaemia in renal disease. Clin Endocrinol (Oxf) (1978) 0.87
Hypercalcaemia secondary to secretion of parathyroid hormone related protein from a somatostatinoma of the pancreas. Ann Clin Biochem (1992) 0.87
Elevation of free thyroxine measurements in patients without thyrotoxicosis. Q J Med (1987) 0.87
Expression of parathyroid hormone-related protein and its receptor in bone metastases from prostate cancer. J Pathol (2000) 0.87
Prevention of venous thromboembolism in surgical patients with breast cancer. Br J Surg (2007) 0.87
Expression of the receptor for parathyroid hormone-related protein in normal and malignant breast tissue. J Pathol (1997) 0.87
Bone metastasis in breast cancer: the role of parathyroid hormone related protein. Surg Oncol (1999) 0.87
Breast macrocysts. World J Surg (1990) 0.86
Parathyroid hormone-related protein (PTHrP) gene expression in solid tumours associated with normocalcaemia and hypercalcaemia. J Pathol (1993) 0.86
Does testosterone affect the normal menstrual cycle? Clin Endocrinol (Oxf) (1986) 0.85
Combination of potassium iodide and propranolol in preparation of patients with Graves' disease for thyroid surgery. N Engl J Med (1980) 0.85
An immunohistochemical study of the tissue distribution of the breast cyst fluid protein, zinc alpha 2 glycoprotein. Histopathology (1987) 0.85
Treatment of the axilla in patients with screen-detected breast cancer. Br J Surg (1993) 0.85
Production of parathyroid-hormone-related protein by cholesteatoma cells in culture. Lancet (1991) 0.85
Parathyroid hormone-related protein in human term placenta and membranes. J Endocrinol (1994) 0.84
Alteration in platelet function in patients with early breast cancer. Anticancer Res (2005) 0.84
Assessment of corpus luteum function by direct radioimmunoassay for progesterone in blood spotted on filter paper. Clin Chem (1985) 0.84
Alopecia and breast disease. BMJ (1997) 0.83
Letter: Thyroid-hormone levels and prognosis in patients with serious non-thyroidal illness. Lancet (1975) 0.83
Successful treatment of an infected vascular graft with gentamicin beads. Eur J Vasc Surg (1987) 0.83
Free perforation in Crohn's colitis. A ten-year review. Dis Colon Rectum (1985) 0.82
Parathyroid hormone-related protein (PTHrP) in breast cancer and benign breast tissue. Eur J Cancer (1995) 0.82